Effect of growth hormone pretreatment on IVF/ICSI-ET assisted pregnancy outcomes in patients with poor ovarian reserve
10.3760/cma.j.cn101441-20220403-00142
- VernacularTitle:生长激素预治疗对卵巢储备功能低下患者IVF/ICSI-ET助孕结局的影响
- Author:
Xiaoyu SHI
1
;
Ningning PAN
;
Caihong MA
Author Information
1. 北京大学第三医院生殖医学中心，北京 100191
- Publication Type:Journal Article
- Keywords:
Growth hormone;
Reproductive technology, assisted;
Poor ovarian reserve;
Poor ovarian response;
POSEIDON criteria
- From:
Chinese Journal of Reproduction and Contraception
2023;43(8):820-824
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of growth hormone (GH) pretreatment on in vitro fertilization/intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET) in women with poor ovarian reserve. Methods:A retrospective cohort study was conducted to analyze the clinical data of women who underwent IVF/ICSI-ET with gonadotropin-releasing hormone (GnRH) antagonist protocol in Reproductive Medicine Center of Peking University Third Hospital from October 2018 to October 2019. Patients with poor ovarian reserve belong POSEIDON group 3 or POSEIDON group 4 were included as the research objects and were divided into GH group ( n=103) and control group ( n=197) by pretreated with GH or not. GH group received 2 U/d subcutaneous injection of GH for 4 weeks before ovulation induction, and the dosage was adjusted to 4 U/d until the trigger day during ovulation induction. GH was not used in control group. The clinical outcomes of the two groups were analyzed and compared. Results:There were no significant differences in general condition between GH group and control group including age, infertility duration, body mass index (BMI), anti-Müllerian hormone (AMH), basal follicle-stimulating hormone (FSH) and antral follicle count (AFC, all P>0.05). No significant differences were found in the duration of gonadotropin (Gn) used, total dosage of Gn used, estrogen levels and the endometrial thickness on human chorionic hormone (hCG) injection day between the two groups (all P>0.05). Furthermore, no statistically significant difference was found in the number of oocytes retrieved between GH group and control group ( P>0.05). The number of available embryos in GH group (2.62±2.41) was significantly higher than that in control group (1.51±1.56, P<0.001). There were 56 fresh embyo transfer cycles in GH group and 106 fresh embyo transfer cycles in control group. There were no statistically significant differences in endometrial thickness on fresh embyo transfer day and the number of embryos transferred between GH group and control group (all P>0.05). No statistically significant differences were found in clinical pregnancy rate, miscarriage rate and live delivery rate after fresh embyo transferred between the two groups (all P>0.05). Conclusion:GH pretreatment for 4 weeks before controlled ovarian sitmulation and continued use till the trigger day may improve number of the available embryos in poor ovarian reserve patients with GnRH antagonist.
